Ikaros and childhood acute lymphoblastic leukemia

doi:10.3760/cma.j.issn.1673-422X.2015.04.021

Abstract

Abstract: Ikaros is a regulatory factor playing an important role in control of the development of hematopoietic cells and immune system; and as a tumor suppressor, its aberration can cause both T and B lineage development arrest and neoplastic transformation, leading to insensitive to therapy and poor prognosis in actue lymphoblastic leukemia. Recently, researches on how Ikaros affects the leukemogenesis and prognosis become the focus of attention.

Key words: Transcription factor, Ikaros, Leukemia, Prognosis

YI Li-Jun-；Duan-Jun-Kai-；Li-Hong. Ikaros and childhood acute lymphoblastic leukemia[J]. Journal of International Oncology, 2015, 42(4): 316-318.

References

［1］ Cobb BS, MoralesAlcelay S, Kleiger G, et al. Targeting of Ikaros to pericentromeric heterochromatin by direct DNA binding［J］. Genes Dev, 2000, 14(17): 21462160. ［2］ Ishimaru F. Expression of Ikaros isoforms in acute lymphoblastic leukemia cell lines［J］. J Clin Oncol, 2000, 18(6): 13951397. ［3］ Dovat S, Payne KJ. Tumor suppression in T cell leukemia—the role of Ikaros［J］. Leuk Res, 2010, 34(4): 416417. ［4］ Meyer C, Zur Stadt U, Escherich G, et al. Refinement of IKZF1 recombination hotspots in pediatric BCPALL patients［J］. Am J Blood Res, 2013, 3(2): 165173. ［5］ Sellars M, Kastner P, Chan S. Ikaros in B cell development and function［J］. World J Biol Chem, 2011, 2(6): 132139. ［6］ Ma S, Pathak S, Mandal M, et al. Ikaros and aiolos inhibit preBcell proliferation by directly suppressing cMyc expression［J］. Mol Cell Biol, 2010, 30(17): 41494158. ［7］ Lo K, Landau NR, Smale ST. LyF1, a transcriptional regulator that interacts with a novel class of promoters for lymphocytespecific genes［J］. Mol Cell Biol, 1991, 11(10): 52295243. ［8］ Georgopoulos K, Moore DD, Derfler B. Ikaros, an early lymphoidspecific transcription factor and a putative mediator for T cell commitment［J］. Science, 1992, 258(5083): 808812. ［9］ Lopez RA, Schoetz S, DeAngelis K, et al. Multiple hematopoietic defects and delayed globin switching in Ikaros null mice［J］. Proc Natl Acad Sci USA, 2002, 99(2): 602607. ［10］ Ng SY, Yoshida T, Zhang J, et al. Genomewide lineagespecific transcriptional networks underscore Ikarosdependent lymphoid priming in hematopoietic stem cells［J］. Immunity, 2009, 30(4): 493507. ［11］ Kim J, Sif S, Jones B, et al. Ikaros DNA binding proteins direct formation of chromatin remodeling complexes in lymphocytes［J］. Immunity, 1999, 10(3): 345355. ［12］ Sridharan R, Smale ST. Predominant interaction of both Ikaros and Helios with the NuRD complex in immature thymocytes［J］. J Biol Chem, 2007, 282(41): 3022730238. ［13］ Kathrein KL, Chari S, Winandy S. Ikaros directly represses the notch target gene Hes1 in a leukemia T cell line: implications for CD4 regulation［J］. J Biol Chem, 2008, 283(16): 1047610484. ［14］ Papaemmanuil E, Hosking FJ, Vijayakrishnan J, et al. Loci on 7p12.2, 10q21.2 and 14q11.2 are associated with risk of childhood acute lymphoblastic leukemia［J］. Nat Genet, 2009, 41(9): 10061010. ［15］ Heerema NA, Nachman JB, Sather HN, et al. Deletion of 7p or monosomy 7 in pediatric acute lymphoblastic leukemia is an adverse prognostic factor: a report from the Children′s Cancer Group［J］. Leukemia, 2004, 18(5): 939947. ［16］ Dupuis A, Gaub MP, Legrain M, et al. Biclonal and biallelic deletions occur in 20% of BALL cases with IKZF1 mutations［J］. Leukemia, 2013, 27(2): 503507. ［17］ Yoshida T, Georgopoulos K. Ikaros fingers on lymphocyte differentiation［J］. Int J Hematol, 2014, 100(3): 220229. ［18］ Virely C, Moulin S, Cobaleda C, et al. Haploinsufficiency of the IKZF1 (IKAROS) tumor suppressor gene cooperates with BCRABL in a transgenic model of acute lymphoblastic leukemia［J］. Leukemia, 2010, 24(6): 12001204. ［19］ Den Boer ML, van Slegtenhorst M, De Menezes RX, et al. A subtype of children acute lymphoblastic leukaemia with poor treatment outcom: a genomewide classification study［J］. Lancet Oncol, 2009, 10(2): 125134. ［20］ Mullighan CG, Miller CB, Radtke I, et al. BCRABL1 lymphoblastic leukaemia is characterized by the deletion of Ikaros［J］. Nature, 2008, 453(7191): 110114. ［21］ Medeiros BC. Deletion of IKZF1 and prognosis in acute lymphoblastic leukemia［J］. N Engl J Med, 2009, 360(17): 470480. ［22］ Krentz S, Hof J, Mendioroz A, et al. Prognostic value of genetic alterations in children with first bone marrow relapse of childhood Bcell precursor acute lymphoblastic leukemia［J］. Leukemia, 2013, 27(2): 295304. ［23］ van der Veer A, Zaliova M, Mottadelli F, et al. IKZF1 status as a prognostic feature in BCRABL1positive childhood ALL［J］. Blood, 2014, 123(11): 16911698.

[1]	Qian Xiaotao, Shi Ziyi, Hu Ge, Wu Xiaowei. Efficacy of consolidation chemotherapy after radical radiotherapy and chemotherapy for stage Ⅲ-ⅣA esophageal squamous cell carcinoma： a real-world clinical study [J]. Journal of International Oncology, 2024, 51(6): 326-331.
[2]	Yang Mi, Bie Jun, Zhang Jiayong, Deng Jiaxiu, Tang Zuge, Lu Jun. Analysis of the efficacy and prognosis of neoadjuvant therapy for locally advanced resectable esophageal cancer [J]. Journal of International Oncology, 2024, 51(6): 332-337.
[3]	Fan Zhipeng, Yu Jing, Hu Jing, Liao Zhengkai, Xu Yu, Ouyang Wen, Xie Conghua. Predictive value of changes in inflammatory markers for prognosis in patients with advanced non-small cell lung cancer treated with the first-line immunotherapy plus chemotherapy [J]. Journal of International Oncology, 2024, 51(5): 257-266.
[4]	Yang Lin, Lu Ning, Wen Hua, Zhang Mingxin, Zhu Lin. Study on the clinical relationship between inflammatory burden index and gastric cancer [J]. Journal of International Oncology, 2024, 51(5): 274-279.
[5]	Liu Pingping, He Xuefang, Zhang Yi, Yang Xu, Zhang Shanshan, Ji Yifei. Risk factors of postoperative recurrence in patients with primary brain glioma and prediction model construction [J]. Journal of International Oncology, 2024, 51(4): 193-197.
[6]	Wan Fang, Yang Gang, Li Rui, Wan Qijing. Expression levels and clinical significance of serum miR-497 and miR-383 in patients with esophageal cancer [J]. Journal of International Oncology, 2024, 51(4): 204-209.
[7]	Yao Yixin, Shen Yulin. Predictive value of serum SOCS3 and TXNIP levels for the prognosis of patients with hepatocellular carcinoma treated with TACE [J]. Journal of International Oncology, 2024, 51(4): 217-222.
[8]	Sun Weiwei, Yao Xuemin, Wang Pengjian, Wang Jing, Jia Jinghao. Exploration of prognostic factors and nomogram construction for advanced non-small cell lung cancer treated with immunotherapy based on hematologic indexes [J]. Journal of International Oncology, 2024, 51(3): 143-150.
[9]	Liu Yulan, Jing Haiyan, Sun Jing, Song Wei, Sha Dan. Advances in predicting efficacy and prognostic markers of immunotherapy for gastric cancer [J]. Journal of International Oncology, 2024, 51(3): 175-180.
[10]	Peng Qin, Cai Yuting, Wang Wei. Advances on KPNA2 in liver cancer [J]. Journal of International Oncology, 2024, 51(3): 181-185.
[11]	Teng Yuan, Li Lijuan, Zhang Liansheng. Progress of MCL-1 and its inhibitors in hematologic malignancies [J]. Journal of International Oncology, 2024, 51(2): 119-122.
[12]	Chen Boguang, Wang Sugui, Zhang Yongjie. Role of serum cholinesterase and inflammatory markers in the prognosis of stage ⅠA -ⅢA breast cancer [J]. Journal of International Oncology, 2024, 51(2): 73-82.
[13]	Jin Xudong, Chen Zhongjian, Mao Weimin. Research progress on the role of MTAP in malignant mesothelioma [J]. Journal of International Oncology, 2024, 51(2): 99-104.
[14]	Huang Zhen, Chen Yongshun. Research progress of circulating tumor DNA in the diagnosis and treatment of hepatocellular carcinoma [J]. Journal of International Oncology, 2024, 51(1): 59-64.
[15]	Wang Xiao, Li Ying, Luo Yujie, Jin Shu. Study on the prognostic value of serological indicators for nasopharyngeal carcinoma based on nomogram model [J]. Journal of International Oncology, 2023, 50(8): 463-469.